The phrase "accelerate approval of" is correct and usable in written English.
It can be used when discussing the need to speed up the process of obtaining approval for something, such as a project, proposal, or request.
Example: "To meet our deadlines, we need to accelerate approval of the new marketing strategy."
Alternatives: "expedite the approval of" or "hasten the approval of".
Based on these studies alone, AstraZeneca asked the FDA for accelerated approval of Iressa on Dec. 28, 2001.
The striking results from clinical trials with crizotinib, the first ALK inhibitor evaluated, allowed the accelerated approval of crizotinib from the USA Food and Drug Administration FDAA).
These products are subjected to the accelerated approval of biological product, the humanitarian device exemption approval, the premarket application approval, the biologics license application approval, and new drug application approval with specific targeting of postapproval registry or surveillance.
This approach of front-loading the development work helped facilitate the accelerated approval of the Biologic License Application for the well-characterized vaccine bivalent rLP2086 (Trumenba®, Pfizer Inc) in 2014 under Breakthrough Therapy Designation.
The debate turned on the FDA's consideration of Inex Pharmaceutical 's application for accelerated approval of Marqibo vincristine sulfate liposome injection to treat relapsed, aggressive non-Hodgkin's lymphoma (NHL).
The recent accelerated approval of eteplirsen (renamed Exondys 51™) by the Food and Drug Administration, for the treatment of Duchenne muscular dystrophy, and nusinersen, for the treatment of spinal muscular atrophy, herald a new and exciting era in splice-switching antisense oligonucleotide applications to treat inherited diseases.
If the tenor of the discussion at the advisory committee is any guide, then the FDA could take a much harder stand when it comes to the accelerated approval of new cancer drugs requiring overwhelming evidence that a drug can melt away the majority of tumors before qualifying it for rapid approval.
The accelerated approval of potent ALK inhibitors, such as crizotinib and more recently ceritinib (LDK378), based on the well designed phase I/II trials has been a landmark success in clinical cancer research and contributes a new era of oncogenic targeted therapy characterized by elegant clinical trial design.
These results led to the accelerated approval of celecoxib for the treatment of FAP.
